Prescription for Better Access

Prescription for Better Access

Por: Mark Hansan and Dr. Scott Howell

With pharmaceutical and biotech manufacturers launching more high-cost specialty drugs and the insurance industry increasing the use of more restrictive barriers to access, those who need these medicines—the patients themselves—are caught in the middle, not only shouldering the cost of higher copays and deductibles, but for many, rationing or even abandoning treatment altogether.

While manufacturers invest in programs to help navigate the challenges impeding access and affordability, the entire healthcare industry can agree -- the status quo is unsustainable. There has to be a better way. And two industry veterans have joined forces to co-host a new interview-focused podcast to help shape the future of patient access and affordability.
35 episodios disponibles

Latest episodes of the podcast Prescription for Better Access

From Policy to the Employer Front Lines: A Conversation with Dan Mendelson of Morgan Health 09/01/2026
Understanding the Impact of the Accelerated Approvals Program 25/11/2025
Charting a Path Forward for More Patient-Centered Value Assessment Methods 17/10/2025
IRA, Part D Redesign & the Future of Drug Access: A Conversation with Jon Blum, Former CMS Principal Deputy Administrator and COO 18/09/2025
The Future of Access, a Live Podcast Recording from the ACCESS US 2025 Conference 17/07/2025
The Domino Effect: 2025 Trends in Specialty Drug Benefits Report 21/05/2025
Inside the Cost Curve: An Interview with Brian Reid 17/04/2025
Value in Prescription Drugs – What Does It Really Mean? 20/03/2025
An interview with Sarah Emond, MPP, President and CEO, Institute for Clinical Economic Review (ICER) 20/02/2025
2025 Outlook with Stacie Dusetzina, Ph.D., Vanderbilt University 18/12/2024
Cell and Gene Therapy Access Challenges 04/12/2024
Global vs. US Drug Pricing and Market Access 22/10/2024
22. Honoring the Work of Healthcare Advocates 12/09/2024
Evolution of PBM's 20/08/2024
How Access Challenges Impact the Drug Development Pipeline 16/07/2024
Interviews from Asembia’s AXS24 Summit, Part 2 04/06/2024
Interviews from Asembia's AXS24 Summit, Part 1 of 2 24/05/2024
Understanding 340B Programs: An Interview with Antonio Ciaccia, CEO, 46brooklyn Research 25/04/2024
Interview with Victor Bulto, President, US, Novartis 28/03/2024
Biosimilar's Role in Improving Patient Access 27/02/2024
1 2 Siguiente › Última »
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA